Natalie Quanquin1, Lulan Wang, Genhong Cheng. 1. aDepartment of Microbiology, Immunology and Molecular Genetics bMolecular Biology Interdepartmental Program, University of California, Los Angeles, California, USA cCenter of System Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing dSuzhou Institute of Systems, Suzhou, Jiangsu, China.
Abstract
PURPOSE OF REVIEW: Zika virus (ZIKV) has only recently been exposed as a significant public health threat, and much of our limited knowledge of its pathogenesis and triggered immune responses were discovered in only the last few years. There are currently no ZIKV-specific therapeutics or vaccines available. This review seeks to bring the reader up-to-date with the latest developments in finding a way to combat this emerging infectious disease. RECENT FINDINGS: Current strategies used for developing ZIKV vaccines or treatments follow proven methods used against other flaviviruses. Unfortunately, ZIKV carries many unique challenges, such as the need to target drugs and vaccines towards immunocompromised populations (pregnant mothers and fetuses), the risk of stimulating harmful immune responses (either autoimmune or antibody-dependent enhancement of infection in those with previous flavivirus exposure), frequently silent infection that may delay treatment and increase risk of transmission to others, and multiple routes of transmission (arthropod vector, sexual, bloodborne, and potentially other body fluids). SUMMARY: Current medical recommendations are directed towards resolving symptoms and not the actual infection; however, ZIKV treatments and vaccines are in development. Vector control and travel restrictions to endemic areas may remain our only available interventions for some time.
PURPOSE OF REVIEW: Zika virus (ZIKV) has only recently been exposed as a significant public health threat, and much of our limited knowledge of its pathogenesis and triggered immune responses were discovered in only the last few years. There are currently no ZIKV-specific therapeutics or vaccines available. This review seeks to bring the reader up-to-date with the latest developments in finding a way to combat this emerging infectious disease. RECENT FINDINGS: Current strategies used for developing ZIKV vaccines or treatments follow proven methods used against other flaviviruses. Unfortunately, ZIKV carries many unique challenges, such as the need to target drugs and vaccines towards immunocompromised populations (pregnant mothers and fetuses), the risk of stimulating harmful immune responses (either autoimmune or antibody-dependent enhancement of infection in those with previous flavivirus exposure), frequently silent infection that may delay treatment and increase risk of transmission to others, and multiple routes of transmission (arthropod vector, sexual, bloodborne, and potentially other body fluids). SUMMARY: Current medical recommendations are directed towards resolving symptoms and not the actual infection; however, ZIKV treatments and vaccines are in development. Vector control and travel restrictions to endemic areas may remain our only available interventions for some time.
Authors: Karin Stettler; Martina Beltramello; Diego A Espinosa; Victoria Graham; Antonino Cassotta; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Stefano Jaconi; Federico Mele; Mathilde Foglierini; Mattia Pedotti; Luca Simonelli; Stuart Dowall; Barry Atkinson; Elena Percivalle; Cameron P Simmons; Luca Varani; Johannes Blum; Fausto Baldanti; Elisabetta Cameroni; Roger Hewson; Eva Harris; Antonio Lanzavecchia; Federica Sallusto; Davide Corti Journal: Science Date: 2016-07-14 Impact factor: 47.728
Authors: Peter Abbink; Rafael A Larocca; Rafael A De La Barrera; Christine A Bricault; Edward T Moseley; Michael Boyd; Marinela Kirilova; Zhenfeng Li; David Ng'ang'a; Ovini Nanayakkara; Ramya Nityanandam; Noe B Mercado; Erica N Borducchi; Arshi Agarwal; Amanda L Brinkman; Crystal Cabral; Abishek Chandrashekar; Patricia B Giglio; David Jetton; Jessica Jimenez; Benjamin C Lee; Shanell Mojta; Katherine Molloy; Mayuri Shetty; George H Neubauer; Kathryn E Stephenson; Jean Pierre S Peron; Paolo M de A Zanotto; Johnathan Misamore; Brad Finneyfrock; Mark G Lewis; Galit Alter; Kayvon Modjarrad; Richard G Jarman; Kenneth H Eckels; Nelson L Michael; Stephen J Thomas; Dan H Barouch Journal: Science Date: 2016-08-04 Impact factor: 47.728
Authors: Rita W Driggers; Cheng-Ying Ho; Essi M Korhonen; Suvi Kuivanen; Anne J Jääskeläinen; Teemu Smura; Avi Rosenberg; D Ashley Hill; Roberta L DeBiasi; Gilbert Vezina; Julia Timofeev; Fausto J Rodriguez; Lev Levanov; Jennifer Razak; Preetha Iyengar; Andrew Hennenfent; Richard Kennedy; Robert Lanciotti; Adre du Plessis; Olli Vapalahti Journal: N Engl J Med Date: 2016-03-30 Impact factor: 91.245
Authors: Stefan Fernandez; Stephen J Thomas; Rafael De La Barrera; Rawiwan Im-Erbsin; Richard G Jarman; Benoît Baras; Jean-François Toussaint; Sally Mossman; Bruce L Innis; Alexander Schmidt; Marie-Pierre Malice; Pascale Festraets; Lucile Warter; J Robert Putnak; Kenneth H Eckels Journal: Am J Trop Med Hyg Date: 2015-02-02 Impact factor: 2.345
Authors: Rafael A Larocca; Peter Abbink; Jean Pierre S Peron; Paolo M de A Zanotto; M Justin Iampietro; Alexander Badamchi-Zadeh; Michael Boyd; David Ng'ang'a; Marinela Kirilova; Ramya Nityanandam; Noe B Mercado; Zhenfeng Li; Edward T Moseley; Christine A Bricault; Erica N Borducchi; Patricia B Giglio; David Jetton; George Neubauer; Joseph P Nkolola; Lori F Maxfield; Rafael A De La Barrera; Richard G Jarman; Kenneth H Eckels; Nelson L Michael; Stephen J Thomas; Dan H Barouch Journal: Nature Date: 2016-06-28 Impact factor: 49.962
Authors: Matthew T Aliota; Elizabeth A Caine; Emma C Walker; Katrina E Larkin; Erwin Camacho; Jorge E Osorio Journal: PLoS Negl Trop Dis Date: 2016-05-23